AOD-9604
C-terminal fragment (Tyr-hGH 177-191) of Growth Hormone. Stimulates lipolysis and inhibits lipogenesis without affinity for the GHR receptor (no IGF-1 effects).
- Burning visceral fat (research)
- No impact on insulin/glucose
- Cartilage recovery (initial studies)
- High safety profileVisceral fat burning (research)
- High security profile
- Local redness.
AOD-9604 is a synthetic peptide fragment corresponding to the C-terminal region (amino acids 176-191) of Human Growth Hormone (hGH), specifically designed to isolate the hormone's lipolytic properties.
READ MORE
What it is (in plain language)
- AOD stands for 'Anti-Obesity Drug'. Unlike full growth hormone, this fragment focuses solely on burning fat (lipolysis) and preventing the formation of new fat cells (lipogenesis). The big advantage is that it doesn't affect blood sugar or the growth of unwanted tissues, as it doesn't stimulate IGF-1 systemically.
Why do you appear online so much
- It is extremely popular in cutting and weight loss protocols. Its fame is due to the fact that it offers the fat-burning benefits of hGH without the risks of insulin resistance or excessive organ growth, and is often used in combination with other peptides to maximise muscle definition.
How it is framed today (pragmatic view)
- 1) Evidence: It has a history of clinical studies for obesity, showing high safety, although efficacy varies according to the user's diet. 2) Objective: Reduction of localised and visceral fat. 3) Risk: It is considered one of the safest peptides, with few reported side effects apart from slight irritation at the application site.
How to use this form
- Analyse the pharmacokinetics in the dosage section. AOD-9604 requires a fasting state for maximum lipolytic efficacy.
- Quick profile (curated by Subject 157)
- Class: Metabolic
- Status: Verified
- Use case: Metabolic
- Route: Injectable
- Tags: Injectable|Fat Loss|Non-Hormonal
- Half-life: ~30 Mins
- Start: Fast
- Duration: ~4-6 hours
- Mechanism (high level)
C-terminal fragment (Tyr-hGH 177-191) of Growth Hormone. Stimulates lipolysis and inhibits lipogenesis without affinity for the GHR receptor (no IGF-1 effects).
- Evidence (what the literature covers)
RESEARCH RANGE (Non-prescriptive):
Common doses in studies range from 300mcg to 500mcg daily.
Level of Evidence: B.
- Safety and harm-reduction (non-prescriptive)
Risks: Local redness.
Interactions: Unknown.
- References (anchors)
- Metzger, D. L. (2000) - AOD9604 metabolic effects in humans - https://doi.org/10.1159/000053183 | PubMed:11155095
- Heffernan, M. (2001) - AOD9604 stimulation of lipolysis via hormone-sensitive lipase - https://doi.org/10.1210/endo.142.12.8522 | PubMed:11713244
Note: Educational/research content. Does not constitute medical advice, diagnosis or prescription.
EN 
PT 
FR 
ES 
DE 
IT 
PL